It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMBBY’s FA Score shows that 0 FA rating(s) are green whileVTAK’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMBBY’s TA Score shows that 4 TA indicator(s) are bullish while VTAK’s TA Score has 4 bullish TA indicator(s).
AMBBY (@Medical/Nursing Services) experienced а -10.23% price change this week, while VTAK (@Medical/Nursing Services) price change was +10.23% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.03%. For the same industry, the average monthly price growth was +0.41%, and the average quarterly price growth was +3.73%.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
AMBBY | VTAK | AMBBY / VTAK | |
Capitalization | 3.79B | 4.44M | 85,348% |
EBITDA | 834M | -13.34M | -6,251% |
Gain YTD | 5.453 | -57.716 | -9% |
P/E Ratio | 63.68 | 0.12 | 51,760% |
Revenue | 5.83B | 481K | 1,212,890% |
Total Cash | 640M | 450K | 142,222% |
Total Debt | 554M | 1.79M | 30,881% |
AMBBY | VTAK | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 28 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 81 | 99 | |
PRICE GROWTH RATING 1..100 | 84 | 94 | |
P/E GROWTH RATING 1..100 | 89 | 7 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VTAK's Valuation (28) in the Medical Specialties industry is significantly better than the same rating for AMBBY (98) in the null industry. This means that VTAK’s stock grew significantly faster than AMBBY’s over the last 12 months.
VTAK's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as AMBBY (100) in the null industry. This means that VTAK’s stock grew similarly to AMBBY’s over the last 12 months.
AMBBY's SMR Rating (81) in the null industry is in the same range as VTAK (99) in the Medical Specialties industry. This means that AMBBY’s stock grew similarly to VTAK’s over the last 12 months.
AMBBY's Price Growth Rating (84) in the null industry is in the same range as VTAK (94) in the Medical Specialties industry. This means that AMBBY’s stock grew similarly to VTAK’s over the last 12 months.
VTAK's P/E Growth Rating (7) in the Medical Specialties industry is significantly better than the same rating for AMBBY (89) in the null industry. This means that VTAK’s stock grew significantly faster than AMBBY’s over the last 12 months.
AMBBY | VTAK | |
---|---|---|
RSI ODDS (%) | 4 days ago59% | 4 days ago83% |
Stochastic ODDS (%) | 4 days ago57% | 4 days ago81% |
Momentum ODDS (%) | 4 days ago71% | 4 days ago88% |
MACD ODDS (%) | 4 days ago68% | 4 days ago90% |
TrendWeek ODDS (%) | 4 days ago66% | 4 days ago82% |
TrendMonth ODDS (%) | 4 days ago70% | 4 days ago90% |
Advances ODDS (%) | N/A | 4 days ago84% |
Declines ODDS (%) | N/A | 6 days ago90% |
BollingerBands ODDS (%) | 4 days ago55% | 4 days ago83% |
Aroon ODDS (%) | 4 days ago72% | 4 days ago90% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
BTCZ | 2.86 | 0.06 | +1.96% |
T-Rex 2X Inverse Bitcoin Daily Target ETF | |||
LEAD | 73.85 | 0.47 | +0.64% |
Siren DIVCON Leaders Dividend ETF | |||
FFEB | 53.53 | 0.29 | +0.54% |
FT Vest US Equity Buffer ETF Feb | |||
XSLV | 45.37 | N/A | N/A |
Invesco S&P SmallCap Low Volatility ETF | |||
NVIR | 30.10 | N/A | N/A |
Horizon Kinetics Energy Remediation ETF |
A.I.dvisor indicates that over the last year, AMBBY has been loosely correlated with ICCM. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if AMBBY jumps, then ICCM could also see price increases.
Ticker / NAME | Correlation To AMBBY | 1D Price Change % | ||
---|---|---|---|---|
AMBBY | 100% | N/A | ||
ICCM - AMBBY | 35% Loosely correlated | -7.21% | ||
MDXH - AMBBY | 34% Loosely correlated | -1.48% | ||
VTAK - AMBBY | 25% Poorly correlated | +6.72% | ||
SAFLF - AMBBY | 24% Poorly correlated | N/A | ||
CLPBY - AMBBY | 23% Poorly correlated | -1.05% | ||
More |
A.I.dvisor tells us that VTAK and AORT have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VTAK and AORT's prices will move in lockstep.
Ticker / NAME | Correlation To VTAK | 1D Price Change % | ||
---|---|---|---|---|
VTAK | 100% | +6.72% | ||
AORT - VTAK | 26% Poorly correlated | +25.23% | ||
ITGR - VTAK | 25% Poorly correlated | +0.69% | ||
AMBBY - VTAK | 25% Poorly correlated | N/A | ||
KRMD - VTAK | 23% Poorly correlated | +2.33% | ||
PODD - VTAK | 22% Poorly correlated | +1.17% | ||
More |